Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Hyperlipidemia
Interventions: AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo, Background Statin Therapy; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 134
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more

Conditions: Hypercholesterolemia, LDL Cholesterol
Interventions: LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Coronary Artery Disease (CAD)
Interventions: Evolocumab, Placebo, Statin therapy; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 38
States / cities: Tempe, Arizona • Los Angeles, California • Mission Viejo, California + 33 more

Conditions: Healthy
Interventions: LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Mixed Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 40
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 37 more

Conditions: HIV Dementia
Interventions: Atorvastatin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin, Lisinopril, Warfarin, Digoxin; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more

Conditions: Rheumatoid Arthritis
Interventions: Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Hyperlipidemia
Interventions: Placebo, MBX-8025, Atorvastatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more

Conditions: Dyslipidemia
Interventions: Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more

Conditions: Healthy
Interventions: Colchicine, Atorvastatin; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: End-Stage Renal Disease
Interventions: Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lupus Erythematosus, Systemic
Interventions: Atorvastatin, Placebo atorvastatin; Drug
Lead sponsor: Laura Schanberg; Other
Eligibility: 10 Years to 21 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypercholesterolemia, Myopathy
Interventions: Not listed
Lead sponsor: Genomas, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: San Francisco, California • Hartford, Connecticut • New York, New York

Conditions: Hepatitis c
Interventions: pioglitazone (Actos), atorvastatin (Lipitor); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Age-related Macular Degeneration
Interventions: Atorvastatin 80mg; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 50 Years to 85 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myocardial Infarction, Hypercholesterolemia
Interventions: alirocumab, placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 13
States / cities: Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin calcium 10 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,311 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 37
States / cities: Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 32 more

Conditions: Sickle Cell Disease
Interventions: Oxypurinol, L-NMMA, Acetylcholine; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

A Study of LY3502970 in Healthy Participants

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Drug-Drug Interaction Study Between Colchicine and Atorvastatin

Pediatric Kidney Transplant Without Calcineurin Inhibitors

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

DNA Diagnostic System for Statin Safety and Efficacy

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

Alirocumab in Patients With Acute Myocardial Infarction

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Actual Use Trial of Atorvastatin Calcium 10 mg

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease